Timeline

The fibrometer is added to the BD Mérieux catalog to test blood coagulation and is quickly adopted by a quarter (approx. 1,000) of France’s laboratories.

• The first toxoplasmosis detection kit: diagnosis of toxoplasmosis by immunofluorescence.
• Launch of miniaturized API^® 20E strip by Api System*

*Api System was acquired by bioMérieux in 1987.

First test enabling the diagnosis of an infectious disease without prior culture, with results in 5 minutes compared to several days previously.

First ATB™ Antibiotic Susceptibility test strip by Api System*

*Api System was acquired by bioMérieux in 1987

*Organon Teknika was acquired by bioMérieux in 2001

A specialist in bacterial identification and antibiotic susceptibility testing systems.

• ATB™ EXPRESSION™ et ATB™ Plus Expert for automated bacterial identification and antibiotic susceptibility testing

A world leader in automated bacterial identification.

国产微拍福利Culture media that enables identification of microbial colonies by coloring them.

Today VIDAS has 100 parameters.

国产微拍福利The first test used to rule out the diagnosis of deep vein thrombosis and pulmonary embolism to be certified by the FDA.

• BacT/ALERT^® 3D an advanced automated system for microbial detection in blood and sterile body fluid samples from Organon Teknika*
• VITEK^® 2 an automated identification and antibiotic susceptibility testing system for bacteria and fungi

国产微拍福利A pioneering company working in HIV screening and viral load measurement.

NucliSENS EasyQ^®国产微拍福利, a molecular diagnostics platform for amplification and real-time detection.

NucliSENS EasyQ^®国产微拍福利 HIV-1, the first real-time test for measuring HIV-1 viral load.

TEMPO^®, for automated enumeration of quality indicators (bacteria, yeast and mold) for the agri-food industry.

VITEK^®国产微拍福利 2 Compact, a system for identification and antibiotic susceptibility testing (AST).

• Acquisition of Biomedics, manufacturer of culture media.
• Acquisition of BTF, a specialist in industrial microbiology.

• Acquisition of AB BIODISK (Sweden), a company internationally recognized for its antimicrobial resistance testing range and particular expertise in susceptibility testing of fastidious and unusual organisms.
•  Acquisition of AviaraDx (USA), now bioTheranostics, a specialist in the molecular diagnosis of tumorous tissues.
•  Acquisition of PML Microbiologicals (USA), a company devoted to the development and production of culture media.
• Joint venture with Sysmex, the Japanese market leader in the field of in vitro diagnostics.
•  Joint venture with Shanghai Kehua Bio-engineering (China) for the production of microplate immunoassays.

PREVI^®国产微拍福利 Color Gram for automated Gram staining.

Acquisition of Meikang Biotech (China), a manufacturer of rapid tests.
 
Acquisition of Shanghai Zenka Biotechnology (China), a specialist in culture media.

• Myla^® middleware is a software solution for the optimization of laboratory workflow and clinical information management. It is a complement to FMLA^® (Full Microbiology Lab Automation).
• BacT/ALERT^® 3D Dual-T, a microbial detection system used for sterility testing in the biopharmaceutical industry.

An industrial microbiology company.

国产微拍福利A specialist in molecular biology.

• Launch of VITEK^® MS (used in association with the VITEK^® 2 system) an automated mass spectrometry microbial identification system for clinical and industrial applications.
• First bioNexia^® rapid tests commercialized by bioMérieux.
• Inauguration of the laboratory of the future at Marcy l’Étoile, France (over 1,000 visits from biologists and scientists in a year). Development of a similar unit in Saint Louis, Missouri (USA). The laboratories enable discussions to align bioMérieux’s future products and services with customer needs.

• Acquisition of RAS, a specialist in molecular biology.
• Partnership with Quanterix for the development of a new generation of ultrasensitive, multiplex immunoassays.

国产微拍福利A companion test for late stage metastatic melanoma tumor samples.

国产微拍福利The new generation of the VIDAS automated immunoassay platform.

Acquisition of BioFire Diagnostics Inc., a privately held US-based company specialized in molecular biology.

The 22-target FilmArray® GI Panel¹ allows a syndromic approach²国产微拍福利 to the diagnosis of infectious diarrhea as it includes bacteria, viruses and parasites in one test.

A test panel is a predetermined group of medical tests used as an aid in the diagnosis and treatment of diseases.

国产微拍福利The syndromic approach is based on analyzing a syndrome (i.e. a set of symptoms) and, with a single reagent, identifying the disease-causing organisms responsible for this syndrome, whether they are viruses, bacteria or parasites.

The new generation of BacT/ALERT^®, VIRTUO™国产微拍福利 is a uniquely innovative automated blood culture microbial detection system.

Strategic partnership in clinical microbiology laboratory automation between bioMérieux and COPAN. Leading manufacturer of innovative pre-analytic solutions, COPAN grants distribution rights for its automated platforms WASP^®国产微拍福利 and WASPLab™.

An innovative next-generation sequencing (NGS) service dedicated to the epidemiological monitoring of bacterial infections. Result of the collaboration agreement with Illumina, a world leader un genomics.

A new-generation PCR system for customers in the agri-food sector for the detection of microorganisms (bacteria and viruses).

国产微拍福利bioMérieux enhances its bioinformatics capabilities with cutting-edge expertise and solutions for the smart use of complex biological data.

The FilmArray^® Torch platform is FDA-cleared for use with the Respiratory, Blood Culture Indentification, Gastrointestinal and Meningitis/Encephalitis panels. It provides up to six times more sample throughput per square foot of benchtop space.

Acquisition of Hyglos, a company that brings bioMérieux a unique and recognized expertise in the development and production of recombinant proteins used for the detection of endotoxins in pharmaceutical products.

国产微拍福利A new automated diagnostic solution for microbial detection in pharmaceutical production and an intelligent incubator system providing real time culture media reading.

A new molecular biology platform for the extraction of nucleic acids (DNA, RNA) that builds on the quality, robustness and ease of use that have made the NucliSENS® easyMAG^® platform so successful. eMAG^® features automation from the primary sample tube, greater traceability and higher throughput, in addition to an unparalleled degree of flexibility, not previously available on an automated system for the extraction of nucleic acids.

国产微拍福利The Compagny’s corporate functions are grouped on a new building in Marcy l’Étoile.

It is located at the roots  of bioMérieux’s geographical center.

The historic site in Marcy concentrates on production, quality and R&D activities.

This automated test for the measurement of procalcitonin (PCT), a biological marker of bacterial infections, is an aid for antibiotic stewardship in respiratory infections and sepsis.

国产微拍福利It provides test results in 20 minutes.

BacT/ALERT^®国产微拍福利 VIRTUO™ is the first continuously-monitoring blood culture microbial detection system to offer “Load & Go” technology, helping labs to streamline their workflow. It is now commercially available in countries that recognize CE marking and in the United States.

The Respiratory BIOFIRE^® FILMARRAY^® 2 (RP2) panel, enriched version of the Respiratory BIOFIRE^® FILMARRAY^® panel, tests in 45 minutes 21 pathogens (17 viruses and 4 bacteria) responsible for respiratory tract infections. It incorporates an additional pathogen, Bordetella parapertussis, one of the causative agents of pertussis or whooping cough.

The BIOFIRE^® FILMARRAY^® RP2 plus includes one additional pathogen: Middle East Respiratory Syndrome coronavirus (MERS-CoV).

国产微拍福利This test was developed for cases where microorganisms are resistant to carbapenems (a very broad spectrum antibiotic class).

Il enables the detection of carbapenemase producers within 2 hours. 

VITEK^® MS, rapid pathogen identification, has received 510(k) clearance from the FDA for the expanded identification of mycobacteria, Nocardia and moulds.

• A  database of  more than 15,000  strains
• For the first time, enables the safe identification of the Mycobacterium tuberculosis (TB) group

国产微拍福利After serving as CEO of bioMérieux for the last three years, Alexandre Mérieux succeeds Jean-Luc Bélingard, who had been Chairman of the Company since 2010.

As the next Mérieux generation takes up the position of Chairman and CEO, this appointment marks the continuity of the family’s role in the Company.

Dedicated to improving the diagnosis of high-risk medical conditions and diseases through the identification and validation of protein biomarkers.

Astute developed the NEPHROCHECK^® test, an FDA-cleared test for the early risk assessment of acute kidney injuries (AKI).

This acquisition follows a development and commercialization partnership signed in 2015 with Astute to develop and market the NEPHROCHECK^® test, for the VIDAS^® automated immunoassay system. It reinforces bioMérieux’s offering of High Medical Value immunoassay biomarkers.

Fruitful partnership developed in 2015 between Astute Medical and bioMérieux when Astute granted bioMérieux a license to develop and market the NEPHROCHECK^® test for the VIDAS^®国产微拍福利 automated immunoassay system

• A new innovative test for the detection of endotoxins in pharmaceutical microbiology control.
• The result of the combined expertise of bioMérieux in microbiology and Hyglos GmbH in endotoxin detection.

The latest additions to the database used by this automated mass spectrometry microbial identification system allows the identification of :

• Brucella, which is often difficult for laboratory staff to recognize
• Emerging antibiotic-resistant pathogens such as Candida auris, Elizabethkingia anophelis and other clinically relevant bacteria.

This innovative solution further improves the performance of the VITEK^® MS system by adding 272 new species to its database, including 217 bacteria species and 55 fungal species.

The Chinese Company Suzhou Hybiome Biomedical Engineering Co.Ltd is specialized in automated immunoassay tests.

Founded in 2009, the company develops, manufactures and markets a complete range of diagnostic solutions (reagents, instruments and software) cleared by the China Food and Drug Administration (CFDA).

The BIOFIRE® FILMARRAY® Pneumonia panel received 510 (k) clearance from the Food and Drug Administration (FDA).

国产微拍福利The BIOFIRE® FILMARRAY® Pneumonia Panel plus received the CE-Mark.

These panels aid in the diagnosis of lower respiratory tract infections.

A company specialized in user-friendly molecular diagnostic tools for the rapid, accurate and reliable detection of pathogens and spoilage organisms in food and beverage.

ARGENE® range test for the detection of SARS-CoV-2 coronavirus.

Emergency Use Authorization by the US Food and Drug Administration (FDA) of the BIOFIRE^® COVID-19 test for the detection of SARS-CoV-2.

国产微拍福利Serology tests used to measure the presence of antibodies in people who have been infected with SARS-CoV-2.